Abhivandan Nagia’s Post

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD

🔬 Detecting blood clots swiftly is crucial in healthcare. D-dimer, a protein fragment produced when blood clots dissolve, serves as a vital biomarker for identifying clot formation in the bloodstream. 💉 Introducing the RapidFor D-Dimer Rapid Test: an advanced diagnostic solution meticulously designed to provide swift and precise results. By measuring D-dimer levels accurately, this test empowers healthcare professionals to promptly diagnose and initiate treatment for thrombotic disorders, ensuring enhanced clinical efficiency and improved patient outcomes. Stay updated on the forefront of clot detection and patient care with the RapidFor D-Dimer Rapid Test. Experience the benefits of cutting-edge technology in healthcare. 🔍💉 📧 For more information on enhancing your laboratory's diagnostic capabilities, please contact us at sales@vitrosens.com. Please read the full blog: https://lnkd.in/dgBaf_vE #DDimer #DDimerRapidTestKit #RapidFor #Vitrosens #VitrosensBiotechnology #InTestWeTrust

ELEVA’s TREATMENT FOR FABRY DISEASE Patients with #Fabry disease face several challenges with biweekly #enzymereplacementtherapy (#ERT) currently on the market. These therapies, while life-saving and critical in managing the disease, present unique obstacles: Frequent Visits: Biweekly infusions of current therapies require significant time for preparation, administration, and observation. This can disrupt personal, professional, and educational commitments. Treatment Fatigue: The biweekly nature of current ERT can lead to burnout and reduced adherence over time. Cost: These therapies are expensive, and even with insurance, co-payments or deductibles can pose a significant financial burden. In many regions, these drugs are either unavailable or prohibitively expensive. In sum, patients receiving currently available ERT for Fabry disease benefit greatly from the treatment but face significant logistical and financial challenges. #Eleva has developed a new recombinant human #alphaGalactosidase (RPV-001) for the treatment of Fabry disease. In a successful #clinicalphase1 study in patients, the compound displayed beneficial safety data. Moreover, the data indicate a possibly significantly longer dose-equivalent treatment interval, reducing the burden for the patient. Finally, the cost-of-goods are distinctly lower by expressing the molecule using #Eleva ‘s unique #moss -based #manufacturing platform (#Bryotechnology ). Meet us during the #JPMorganHealthWeek to learn about this asset and discuss possibilities to cooperate in its further development.

A patient-led organization has just made an incredible breakthrough by repurposing a drug for a rare and deadly bleeding condition! Recently, a large clinical trial revealed that pomalidomide, originally developed for multiple myeloma, has proven effective in treating a life-threatening bleeding disorder called HHT (Hereditary Hemorrhagic Telangiectasia). This drug not only reduced bleeding events but also improved patients’ quality of life. Cure HHT brought together physicians, researchers, and patients to push this repurposing opportunity forward, showing the true power of patient-led organizations. At Every Cure, we aim to work closely with patient organizations to identify the most promising opportunities from our platform and ensure the necessary trials are conducted to benefit as many patients as possible. Because no one understands a rare disease better than those living with it. #raredisease #drugdevelopment #drugrepurposing #clinicaltrial

$IMMX IMMIX: Positive Clinical Data FromFirst 4 patients in the CAR-T trial for amyloidosis achieved normalized disease markers! 🎉 2 are complete responders, and 2 are bone marrow negative. ⌛️next program update in H1 2025. Interim clinical data expected Q2/Q3 2025. Final topline clinical data expected Q2/Q3 2026 #Biotech #Healthcare https://lnkd.in/gFHqAsM9

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/e4-geiYJ   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eutVZQcX #creativemedical #celz #nasdaq #biotech

Digital Therapeutics: The Future Of Personalized Medicine! In this article, our CEO Ayush Jain, discusses the transformative potential of digital therapeutics (DTx) in the healthcare industry. As chronic diseases become more prevalent, the need for tailored, evidence-based treatment solutions has never been greater. Discover how DTx is reshaping chronic disease management, enhancing patient engagement, and paving the way for a more holistic, patient-centered healthcare future. Read the full article here. 👇 https://lnkd.in/dyuQr2Qx #DigitalHealth #PersonalizedMedicine #ChronicDisease #Innovation #HealthcareTechnology Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare FDA McKinsey & Company Pravin Uttarwar Manisha Khadge

Did you know that chronic diseases account for a whopping 84% of deaths globally? That's a staggering number. Digital therapeutics (DTx) are transforming the way we treat chronic conditions. These aren't just apps; they're evidence-based treatments delivered right to your smartphone for personalized care, improved engagement, and better outcomes for chronic conditions like diabetes, hypertension, and mental health. Read the article to learn more! Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare BioSpace McKinsey & Company FDA Manisha Khadge Pravin Uttarwar #digitaltherapeutics #personalizedmedicine #healthcare #wellness #healthtech #futureofhealthcare

The hidden dangers of prediabetes   Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease.   https://lnkd.in/ePRuM_bD   The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.    As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.    For more information on the CELZ-201 trial, visit https://lnkd.in/eZ8FAwYB #creativemedical #celz #nasdaq #biotech

The report below is an example of a patient in a long-term care facility that has a positive UA and suffering from a UTI. What is remarkable about this case? 1. UA is positive so patient has a UTI 2. Patient has resistance to multiple classes of antibiotics. Why? Because they have been throwing antibiotics at her not knowing what they are treating! 3. The bacterial level is HIGH! 4. Patient's urine has 100% of one microbe, Raoultella ornithinolytica, a species that is a known pathogen. 5. While many UTIs are caused by multiple microorganisms, creating a challenges on interpretation, in this case only a single bacteria was detected. Traditional culture techniques rarely detect this species. This species is not commonly found on PCR panels and would have been missed. MicroGenDX is the best diagnostic tool to have the most accurate identification and allow targeted treatment! Learn more: https://loom.ly/WdQj5xg #UTI #InfectionTesting #AccurateDiagnosis #PatientCare #NextGenerationSequencing #UTITesting #UTIDiagnosis #AntibioticResistance #PrecisionMedicine #MicroGenDX